The DOI matches its Crossref record; 196 of the 211 references it cites were found in a registry or an index.
Tumor-infiltrating T lymphocytes: friends or foes?
Open accessAbstract
The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been a longstanding topic of debate. In cases where TILs have improved patient outcome, T lymphocytes are recognized as the main effectors of antitumor immune responses. However, recent studies have revealed that a subset of CD4(+) T cells, referred to as CD4(+)CD25(+) regulatory T cells (Treg), may accumulate in the tumor environment and suppress tumor-specific T-cell responses, thereby hindering tumor rejection. Hence, predicting tumor behavior on the basis of an indiscriminate evaluation of tumor-infiltrating T cells may result in inconsistent prognostic accuracy. The presence of infiltrating CD4(+)CD25(+) Treg may be detrimental to the host defense against the tumor, while the presence of effector T lymphocytes, including CD8(+) T cells and non-regulatory CD4(+) helper T cells may be beneficial. Enhanced recruitment of antitumor effector T lymphocytes to tumor tissue in addition to inhibition of local Treg, may therefore be an ideal target for improving cancer immunotherapy. This article reviews the antitumor functions of T-lymphocytes, with special attention given to CD4(+) regulatory T-cells within the tumor environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD8+ T cells and CD4+ effector T cells have demonstrated anti-cancer potential, while regulatory T cells (CD4+ CD25+ Tregs) have been shown to be able to contribute to the attenuated immune response exhibited in cancer [65,66].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678
The expanding universe of T-cell subsets: Th1, Th2 and more
Mosmann, T. R., & Sad, S. (1996) · Immunology Today · doi:10.1016/0167-5699(96)80606-2 · Cited by 3,603
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M., Ferguson, P., Whitesell, L., Kelly, T., Saulsbury, F., Chance, P., & Ochs, H. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,576
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Sakaguchi, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,315
Research works printed but not linked: 1
- Allione, 1994, Cancer Res, 54, 6022
Cited by
Sorted by citations
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,296
Gao, Q., Qiu, S., Fan, J., Zhou, J., Wang, X., Xiao, Y., Xu, Y., Li, Y., & Tang, Z. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,134
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897
Self-citationHe, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729
Self-citationThe tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 540
Leffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B. N., ten Hoor, K. A., Hollema, H., Boezen, H. M., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0583-5 · Cited by 416
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 310
Self-citationLiu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G. A., Fan, Y., Yin, D., Gu, F., Yao, Z., & Fu, L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1647-3 · Cited by 310
Fu, Q., Chen, N., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., Song, X., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593806 · Cited by 283
Sun, T., Gao, Y., Tan, W., Ma, S., Shi, Y., Yao, J., Guo, Y., Yang, M., Zhang, X., Zhang, Q., et al. (2007) · Nature Genetics · doi:10.1038/ng2030 · Cited by 269
Shah, W., Yan, X., Li, J., Zhou, Y., Chen, H., & Wang, Y. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.56 · Cited by 266
Kang, J., Choi, Y. J., Kim, I.-K., Lee, H. S., Kim, H., Baik, S. H., Kim, N. K., & Lee, K. Y. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.974 · Cited by 262
Jordanova, E. S., Gorter, A., Ayachi, O., Prins, F., Durrant, L. G., Kenter, G. G., van der Burg, S. H., & Fleuren, G. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4554 · Cited by 233
CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
Oshi, M., Asaoka, M., Tokumaru, Y., Yan, L., Matsuyama, R., Ishikawa, T., Endo, I., & Takabe, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186968 · Cited by 212
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances
Dhanasekaran, R., Bandoh, S., & Roberts, L. R. (2016) · F1000Research · doi:10.12688/f1000research.6946.1 · Cited by 214
Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
Ruffini, E., Asioli, S., Filosso, P. L., Lybéris, P., Bruna, M. C., Macrì, L., Daniele, L., & OLIARO, A. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.10.067 · Cited by 205
Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1651-7 · Cited by 196
Shen, Z., Zhou, S., Wang, Y., Li, R., Zhong, C., Liang, C., & Sun, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0816-9 · Cited by 201
Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Schreck, S., Friebel, D., Buettner, M. J., Distel, L. V., Grabenbauer, G. G., Young, L. S., & Niedobitek, G. (2008) · Hematological Oncology · doi:10.1002/hon.878 · Cited by 200
An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0987-8 · Cited by 191
Matsumoto, H., Thike, A. A., Li, H., Yeong, J. P.-S., Koo, S., Dent, R. A., Tan, P. H., & Iqbal, J. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3743-x · Cited by 167
Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet
Lussier, D. M., Woolf, E. C., Johnson, J. L., Brooks, K. S., Blattman, J. N., & Scheck, A. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2337-7 · Cited by 167
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Anraku, M., Cunningham, K. S., Yun, Z., Tsao, M., Li, Z., Keshavjee, S. H., Johnston, M. R., & de Perrot, M. E. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.026 · Cited by 157
Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer
Ngan, C. Y., Yamamoto, H., Seshimo, I., Tsujino, T., Man-i, M., Ikeda, J.-I., Konishi, K., Takemasa, I., Ikeda, M., Sekimoto, M., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603651 · Cited by 150
Watanabe, Y., Katou, F., Ohtani, H., Nakayama, T., Yoshie, O., & Hashimoto, K. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.12.015 · Cited by 159
Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
Zhang, Y.-L., Li, J., Mo, H., Qiu, F., Zheng, L., Qian, C.-N., & Zeng, Y.-X. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-4 · Cited by 149
Ong, S., Tan, Y., Beretta, O., Jiang, D., Yeap, W., Tai, J. J. Y., Wong, W., Yang, H., Schwarz, H., Lim, K., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141825 · Cited by 145
Bronkhorst, I. H. G., Vu, T. H. K., Jordanova, E. S., Luyten, G. P. M., van der Burg, S. H., & Jager, M. J. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9280 · Cited by 141
Yu, Y., Qian, L., & Cui, J. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1342 · Cited by 132
Diepstra, A., Imhoff, G. W. V., Karim‐Kos, H. E., van den Berg, A., Meerman, G. J. T., Niens, M., Nolte, I. M., Bastiaannet, E., Schaapveld, M., Vellenga, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.0917 · Cited by 131
Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
Kúdelová, E., Smolár, M., Holubeková, V., Horňáková, A., Dvorská, D., Lučanský, V., Koklesová, L., Kúdela, E., & Kubatka, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314937 · Cited by 127
Recent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 132
Baker, K., Lachapelle, J., Zlobec, I., Bismar, T. A., Terracciano, L., & Foulkes, W. D. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03846.x · Cited by 121
High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
Flammiger, A., Weisbach, L., Huland, H., Tennstedt, P., Simon, R., Minner, S. J. P., Bokemeyer, C., Sauter, G., Schlomm, T., & Trepel, M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.035 · Cited by 124
Colitis-associated cancer: the role of T cells in tumor development
Waldner, M. J., & Neurath, M. F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0161-8 · Cited by 124
Derhovanessian, E., Adams, V., Hähnel, K., Groeger, A., Pandha, H., Ward, S., & Pawelec, G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24497 · Cited by 122
Yang, Y., Xiu, F., Cai, Z., Wang, J., Wang, Q., Fu, Y., & Cao, X. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0184-7 · Cited by 116
Self-citationIncreased Glioma Growth in Mice Depleted of Macrophages
Galarneau, H., de Villeneuve, J. P., Gowing, G., Julien, J., & Vallières, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0177 · Cited by 113
Rodrigues, P. C., Miguel, M. C. D. C., Bagordakis, E., Fonseca, F. P., de Aquino, S. N., Santos‐Silva, A. R., Lopes, M. A., Graner, E., Salo, T. A., Kowalski, L. P., et al. (2014) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2014.01.014 · Cited by 112
Ohtani, H., Jin, Z. H., Takegawa, S., Nakayama, T., & Yoshie, O. (2008) · The Journal of Pathology · doi:10.1002/path.2448 · Cited by 111
Choi, Y., Kim, J. W., Nam, K. H., Han, S.-H., Kim, J., Ahn, S.-H., Park, D. J., Lee, K., Lee, H. S., & Kim, H. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0642-0 · Cited by 110
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Đačić, S., Shuai, Y., Yousem, S. A., Ohori, P. N., & Nikiforova, M. N. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.154 · Cited by 108
Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types
van der Kooij, M. K., Speetjens, F. M., van der Burg, S. H., & Kapiteijn, E. (2019) · Cancers · doi:10.3390/cancers11060845 · Cited by 107
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 113
Landskron, J., Helland, Ø., Torgersen, K. M., Aandahl, E. M., Gjertsen, B. T., Bjørge, L., & Taskén, K. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1636-6 · Cited by 102
Role of inflammatory infiltrates in triple negative breast cancer
Matsumoto, H., Koo, S., Dent, R. A., Tan, P. H., & Iqbal, J. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202944 · Cited by 99
Development of a Listeria monocytogenes based vaccine against prostate cancer
Shahabi, V., Reyes-Reyes, M., Wallecha, A., Rivera, S., Paterson, Y. Y. W., & Maciag, P. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0463-z · Cited by 95
Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
Thirukkumaran, C. M., Nodwell, M. J., Hirasawa, K., Shi, Z.-Q., Diaz, R., Luider, J. M., Johnston, R. N., Forsyth, P. A., Magliocco, A. M., Lee, P. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2408 · Cited by 95
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 99
Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., & Rossi, L. E. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.013 · Cited by 93
Zhang, S., Fujita, H., Mitsui, H., Yanofsky, V. R., Fuentes‐Duculan, J., Pettersen, J. S., Suárez‐Fariñas, M., Gonzalez, J., Wang, C. Q. F., Krueger, J. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062154 · Cited by 93
Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer
Yang, M., Sun, T., Wang, L., Yu, D., Zhang, X., Miao, X., Liu, J., Zhao, D., Li, H., Tan, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0177 · Cited by 89
Colon cancer and the immune system: The role of tumor invading T cells
Waldner, M. J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i45.7233 · Cited by 92
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer.
Peng, G., Li, L., Guo, Y., Yu, P., Yin, X., Wang, S., & Liu, C. (2019) · Europe PMC (PubMed Central) · Cited by 87
Self-citationHistone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
Cao, K., Wang, G., Li, W., Zhang, L., Wang, R., Huang, Y., Du, L., Jiang, J., Wu, C., He, X., et al. (2015) · Oncogene · doi:10.1038/onc.2015.46 · Cited by 91
Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors
Mrass, P., & Weninger, W. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00433.x · Cited by 87
Fujii, H., Arakawa, A., Utsumi, D., Sumiyoshi, S., Yamamoto, Y., Kitoh, A., Ono, M., Matsumura, Y., Kato, M. K., Konishi, K., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28581 · Cited by 92
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer
Flammiger, A., Bayer, F., Cirugeda‐Kühnert, A., Huland, H., Tennstedt, P., Simon, R., Minner, S. J. P., Bokemeyer, C., Sauter, G., Schlomm, T., et al. (2012) · Apmis · doi:10.1111/j.1600-0463.2012.02924.x · Cited by 87
Pölcher, M., Braun, M., Friedrichs, N., Rudlowski, C., Bercht, E., Fimmers, R., Sauerwald, A., Keyver-Paik, M.-D., Kübler, K., Büttner, R., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0817-1 · Cited by 89
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 95
Halama, N., Michel, S., Kloor, M., Zoernig, I., Pommerencke, T., Doeberitz, M. V. K., Schirmacher, P., Weitz, J., Grabe, N., & Jäger, D. (2009) · PubMed Central · Cited by 81
Differential infiltration of CD8+and NK cells in lip and oral cavity squamous cell carcinoma
Zancopé, E., Costa, N. L., Junqueira‐Kipnis, A. P., Valadares, M. C., Silva, T. A., Leles, C. R., Mendonça, E. F., & Batista, A. C. (2009) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2009.00792.x · Cited by 79
Rathore, A. S., Kumar, S., Konwar, R., Makker, A., Negi, M. P. S., & Goel, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 77
García-Hernández, M. D. L. L., Uribe‐Uribe, N., Espinosa-González, R., Kast, W. M., Khader, S. A., & Rangel‐Moreno, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00563 · Cited by 77
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Nallasamy, P., Chava, S. P., Verma, S. S., Mishra, S., Gorantla, S., Coulter, D. W., Byrareddy, S. N., Batra, S. K., Gupta, S. C., & Challagundla, K. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.009 · Cited by 75
Kistner, L., Doll, D., Holtorf, A., Nitsche, U., & Janssen, K. (2017) · Oncotarget · doi:10.18632/oncotarget.21286 · Cited by 75
Radosavljevic, G. D., Jovanović, I., Majstorović, I., Mitrović, M., Lisnić, V. J., Arsenijević, N., Jonjić, S., & Lukić, M. L. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9383-y · Cited by 73
Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy
Chandrasekaran, S., & King, M. R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120209 · Cited by 74
Loss of CTL Function among High-Avidity Tumor-Specific CD8+ T Cells following Tumor Infiltration
Janicki, C. N., Jenkinson, S. R., Williams, N., & Morgan, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5008 · Cited by 72
Xin Min, Z. H. O. U., Du, Y., Xu, J. L., Huang, Z., Qiu, T., Wang, X., Qian, J., Zhu, W., & Liu, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-2504-x · Cited by 66
Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management
Shirabe, K., Motomura, T., Muto, J., Toshima, T., Matono, R., Mano, Y., Takeishi, K., Ijichi, H., Harada, N., Uchiyama, H., et al. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0131-0 · Cited by 66
Cui, G., Goll, R., Olsen, T., Steigen, S. E., Husebekk, A., Vonen, B., & Florholmen, J. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0259-y · Cited by 66
Jackutė, J., Žemaitis, M., Pranys, D., Šitkauskienė, B., Miliauskas, S., Bajoriūnas, V., Lavinskienė, S., & Sakalauskas, R. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0108-x · Cited by 64
Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis
Zhao, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7971 · Cited by 64
Wang, W., Hodkinson, P. S., McLaren, F., Mackean, M., Williams, L. J., Howie, S., Wallace, W. A., & Sethi, T. (2013) · CHEST Journal · doi:10.1378/chest.12-0681 · Cited by 64
IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition
Gaggianesi, M., Turdo, A., Chinnici, A., Lipari, E., Apuzzo, T., Benfante, A., Sperduti, I., Franco, S. D., Meraviglia, S., Presti, E. L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3126 · Cited by 62
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma
Kogashiwa, Y., Yasuda, M., Sakurai, H., Nakahira, M., Sano, Y., Gonda, K., Ikeda, T., Inoue, H., Kuba, K., Oba, S., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11465 · Cited by 63
Kraja, F., Jurišić, V., Hromić-Jahjefendić, A., Rossopoulou, N., Κάτσιλα, Θ., Martinović, K. M., Rivas, J. D. L., Diaconu, C. C., & Szöőr, Á. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601773 · Cited by 71
Jiang, W., Liu, K., Guo, Q., Cheng, J., Shen, L., Cao, Y., Wu, J., Shi, J., Cao, H., Liu, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17602 · Cited by 58
T Cells in Gastric Cancer: Friends or Foes
Amedei, A., Bella, C. D., Silvestri, E., Prisco, D., & D’Elios, M. M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/690571 · Cited by 56
Dendritic cells and cytokines in immune rejection of cancer
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.003 · Cited by 57
Differential modulation and prognostic values of immune-escape genes in uveal melanoma
Basile, M. S., Mazzon, E., Russo, A., Mammana, S., Longo, A., Bonfiglio, V. M. E., Fallico, M., Caltabiano, R., Fagone, P., Nicoletti, F., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210276 · Cited by 56
Chang, W., Li, C., Huang, S., Chang, D., Chou, L., & Sheu, B. (2010) · Cancer · doi:10.1002/cncr.25371 · Cited by 56
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Bupathi, M., & Wu, C. S.-Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.07.03 · Cited by 57
Rauser, S., Langer, R., Tschernitz, S., Gais, P., Jütting, U., Feith, M., Höfler, H., & Walch, A. K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-608 · Cited by 53
Nagai, S., Abouljoud, M. S., Kazimi, M. M., Brown, K., Moonka, D., & Yoshida, A. (2013) · Transplantation · doi:10.1097/01.tp.0000437426.15890.1d · Cited by 52
Kim, H., Kim, H., Cho, H. W., Kim, S. Y., Song, K., Hyung, W. J., Park, C., & Kim, C. G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22038 · Cited by 52
Nierenberg, N. E., Poutsiaka, D. D., Chow, J. K. L., Cooper, J. T., Price, L. L., Freeman, R. B., Rohrer, R., & Snydman, D. R. (2014) · Liver Transplantation · doi:10.1002/lt.23991 · Cited by 51
Yang, K. R., Mooney, S. M., Zarif, J. C., Coffey, D. S., Taichman, R. S., & Pienta, K. J. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24813 · Cited by 50
Koustas, E., Sarantis, P., Kyriakopoulou, G., Papavassiliou, A. G., & Karamouzis, M. V. (2019) · Cancers · doi:10.3390/cancers11040533 · Cited by 50
Capriotti, E., Vonderheid, E. C., Thoburn, C. J., Wasik, M. A., Bahler, D. W., & Hess, A. D. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802064917 · Cited by 48
Romero-Cordoba, S. L., Meneghini, E., Sant, M., Iorio, M. V., Sfondrini, L., Paolini, B., Agresti, R., Tagliabue, E., & Bianchi, F. (2019) · Cancers · doi:10.3390/cancers11070911 · Cited by 47
Mattarollo, S. R., Steegh, K., Li, M., Duret, H., Ngiow, S. F., & Smyth, M. J. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.58 · Cited by 46
KIF2C Is a Novel Prognostic Biomarker and Correlated with Immune Infiltration in Endometrial Cancer
An, L., Zhang, J., Feng, D., Zhao, Y., Ouyang, W., Shi, R., Zhou, X., Yu, Z., Wei, S., Min, J., et al. (2021) · Stem Cells International · doi:10.1155/2021/1434856 · Cited by 46
The tumour microenvironment and implications for cancer immunotherapy
Petrulio, C., Kim‐Schulze, S., & Kaufman, H. L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.7.671 · Cited by 45
Immunomodulatory Yersinia outer proteins (Yops)–useful tools for bacteria and humans alike
Grabowski, B., Schmidt, M. A., & Rüter, C. (2017) · Virulence · doi:10.1080/21505594.2017.1303588 · Cited by 47
Kim, A. R., Choi, K. S., Kim, S. K., Kim, K., Kang, H. J., Kim, S., Chowdhury, T., Yu, H. J., Lee, C. E., Lee, J. H., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02836-w · Cited by 44
Cancer–Testis Genes as Candidates for Immunotherapy in Breast Cancer
Ghafouri‐Fard, S., Shams, R., Seifi‐Alan, M., Javaheri, M., & Tabarestani, S. (2014) · Immunotherapy · doi:10.2217/imt.13.165 · Cited by 44
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
Ahmed, M. E., Falasiri, S. S. A., Hajiran, A. J., Chahoud, J., & Spiess, P. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103334 · Cited by 45
Metadata
- Authors
- Yu, P., & Fu, Y.-X.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Yu, Ping
- Fu, Yang-Xin
- ORCID
- Fu, Yang-Xin
- Venue
- Laboratory Investigation
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 86
- Issue
- 3
- Pages
- 231-245
- ISSN
- 0023-6837 (ISSN-L)
- OpenAlex
- W2061590134
- Cited by
- 299
- References
- 211
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 15 · 2021: 20 · 2020: 13 · 2019: 15 · 2018: 8 · 2017: 18 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 11 · 2012: 17
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Laboratory Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, regulatory T cells, CD4+CD25+ T cells, CD8+ T cells, CD4+ T helper cells, antitumor immunity, tumor immunosuppression, prognostic value, cancer immunotherapy
- MeSH terms
- Humans, Neoplasms, Prognosis, CD4-Positive T-Lymphocytes, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
